Individual determinations of %V617F over time in the 29 mutated patients
| Patient no. . | 9pLOH . | Month 0 . | Month 6 . | Month 12 . | Month 18 . | Month 24 . | Month 30 . | Month 36 . |
|---|---|---|---|---|---|---|---|---|
| 1 | 50 | 15 | 10 | 10 | 10 | 10 | 5 | |
| 2 | 20 | 5 | 5 | ND | 1 | 0 | 0 | |
| 3 | − | 50 | 40 | 40 | 25 | 20 | 10 | 10 |
| 4 | + | 100 | 50 | 50 | 45 | 45 | 45 | 40 |
| 5 | 40 | 40 | 20 | 20 | 20 | 15 | 5 | |
| 6 | 50 | 50 | 0 | 0 | 0 | 0 | ||
| 7 | 100 | 50 | 45 | 30 | ||||
| 8 | 25 | 25 | 10 | 5 | 5* | 5* | ||
| 9 | 100 | 85 | 50 | 15 | 5 | 0* | 0* | |
| 10 | + | 70 | 55 | 45 | ||||
| 11 | 40 | 40 | 40 | 40* | ||||
| 12 | 10 | 5 | 5 | 5* | 5* | 0* | 0* | |
| 13 | − | 40 | 25 | 25 | 25 | 25 | ||
| 14 | 40 | 25 | 20 | 20 | ||||
| 15 | + | 50 | 45 | 30 | 30 | |||
| 16 | + | 80 | 45 | 25 | ND | 10 | 10 | 1 |
| 17 | + | 45 | 35 | 25 | ND | 5 | ||
| 18 | + | 60 | 60 | 45 | 10* | 10* | ||
| 19 | − | 40 | 20 | 20 | 5 | 5 | 5 | |
| 20 | − | 20 | 20 | 10 | 5 | 5* | 5* | |
| 21 | 35 | 20 | 20 | 10 | 1 | 1 | ||
| 22 | − | 20 | 10 | 5 | 0* | |||
| 23 | 10 | 10 | 10 | ND | 10 | |||
| 24 | − | 40 | 10 | 10 | 5 | 1 | ||
| 25 | + | 65 | 45 | 45 | ND* | 0* | 0* | |
| 26 | 50 | ND | 50 | 40* | ||||
| 27 | 45 | 25 | ND | 25 | 25 | |||
| 28 | − | 65 | 50 | 50 | 50 | |||
| 29 | − | 45 | 10 | 0 | 0* | 0* | 0* |
| Patient no. . | 9pLOH . | Month 0 . | Month 6 . | Month 12 . | Month 18 . | Month 24 . | Month 30 . | Month 36 . |
|---|---|---|---|---|---|---|---|---|
| 1 | 50 | 15 | 10 | 10 | 10 | 10 | 5 | |
| 2 | 20 | 5 | 5 | ND | 1 | 0 | 0 | |
| 3 | − | 50 | 40 | 40 | 25 | 20 | 10 | 10 |
| 4 | + | 100 | 50 | 50 | 45 | 45 | 45 | 40 |
| 5 | 40 | 40 | 20 | 20 | 20 | 15 | 5 | |
| 6 | 50 | 50 | 0 | 0 | 0 | 0 | ||
| 7 | 100 | 50 | 45 | 30 | ||||
| 8 | 25 | 25 | 10 | 5 | 5* | 5* | ||
| 9 | 100 | 85 | 50 | 15 | 5 | 0* | 0* | |
| 10 | + | 70 | 55 | 45 | ||||
| 11 | 40 | 40 | 40 | 40* | ||||
| 12 | 10 | 5 | 5 | 5* | 5* | 0* | 0* | |
| 13 | − | 40 | 25 | 25 | 25 | 25 | ||
| 14 | 40 | 25 | 20 | 20 | ||||
| 15 | + | 50 | 45 | 30 | 30 | |||
| 16 | + | 80 | 45 | 25 | ND | 10 | 10 | 1 |
| 17 | + | 45 | 35 | 25 | ND | 5 | ||
| 18 | + | 60 | 60 | 45 | 10* | 10* | ||
| 19 | − | 40 | 20 | 20 | 5 | 5 | 5 | |
| 20 | − | 20 | 20 | 10 | 5 | 5* | 5* | |
| 21 | 35 | 20 | 20 | 10 | 1 | 1 | ||
| 22 | − | 20 | 10 | 5 | 0* | |||
| 23 | 10 | 10 | 10 | ND | 10 | |||
| 24 | − | 40 | 10 | 10 | 5 | 1 | ||
| 25 | + | 65 | 45 | 45 | ND* | 0* | 0* | |
| 26 | 50 | ND | 50 | 40* | ||||
| 27 | 45 | 25 | ND | 25 | 25 | |||
| 28 | − | 65 | 50 | 50 | 50 | |||
| 29 | − | 45 | 10 | 0 | 0* | 0* | 0* |
LOH indicates loss of heterozygosity; and ND, not done.
Samples taken after peg-IFNα -2a discontinuation.